Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.45 |
| ▸ | SSTR5 | P35346 | 6/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2999026 | 1.00 | OPRM1 (0.53) | OPRM1SIGMAR1NPY5RADRA1AKCNH2 | |
| SCHEMBL3000010 | 1.00 | OPRM1 (0.53) | OPRM1SIGMAR1NPY5RADRA1AKCNH2 | |
| SCHEMBL3673029 | 0.88 | NPY5R (0.48) | OPRM1SIGMAR1NPY5RADRA1AKCNH2 | |
| SCHEMBL3036032 | 0.88 | NPY5R (0.48) | OPRM1SIGMAR1NPY5RADRA1AKCNH2 | |
| SCHEMBL3004640 | 0.86 | NPY5R (0.51) | OPRM1SIGMAR1NPY5RADRA1AKCNH2 | |
| SCHEMBL3010768 | 0.86 | NPY5R (0.51) | OPRM1SIGMAR1NPY5RADRA1AKCNH2 | |
| SCHEMBL3004639 | 0.86 | NPY5R (0.51) | OPRM1SIGMAR1NPY5RADRA1AKCNH2 | |
| SCHEMBL3028152 | 0.84 | HSD11B1 (0.48) | OPRM1SIGMAR1NPY5RADRA1AKCNH2 | |
| SCHEMBL3669039 | 0.84 | HSD11B1 (0.48) | OPRM1SIGMAR1NPY5RADRA1AKCNH2 | |
| SCHEMBL3031924 | 0.83 | NPY5R (0.48) | OPRM1SIGMAR1NPY5RADRA1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286151-A1 | 1-OXA-3-Azaspiro[4,5]Decan--2-One Derivatives For The Treatment Of Eating Disorders | BENTLEY JONATHAN | 2010-11-11 | — | — | US | disclosed |
| US-20100216821-A1 | Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 Antagonists | BARTON NICHOLAS PAUL | 2010-08-26 | — | — | US | disclosed |
| US-20100216821-A1 | Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 Antagonists | BARTON NICHOLAS PAUL | 2010-08-26 | — | — | US | disclosed |
| US-20100197699-A1 | I-OXA-3-Azaspiro (4.5) Decan-2-One And 1-OXA-3, 8-Diazaspiro (4.5) Decan-2-One Derivatives For The Treatment of Eating Disorders | GLAXO GROUP LIMITED | 2010-08-05 | — | — | US | disclosed |
| US-20100197699-A1 | I-OXA-3-Azaspiro (4.5) Decan-2-One And 1-OXA-3, 8-Diazaspiro (4.5) Decan-2-One Derivatives For The Treatment of Eating Disorders | GLAXO GROUP LIMITED | 2010-08-05 | — | — | US | disclosed |
| US-20100197699-A1 | I-OXA-3-Azaspiro (4.5) Decan-2-One And 1-OXA-3, 8-Diazaspiro (4.5) Decan-2-One Derivatives For The Treatment of Eating Disorders | GLAXO GROUP LIMITED | 2010-08-05 | — | — | US | disclosed |
| EP-2139861-A1 | BENZIMIDAZOLES WITH A HETERO SPIRO-DECANE RESIDUE AS NPY-Y5 ANTAGONISTS | Glaxo Group Limited (GB) | 2010-01-06 | — | — | EP | disclosed |
| EP-2121673-A1 | I-OXA-3-AZASPIRO (4.5) DECAN-2-ONE AND 1-OXA-3, 8-DIAZASPIRO (4.5) DECAN-2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS | Glaxo Group Limited (GB) | 2009-11-25 | — | — | EP | disclosed |
| EP-2118097-A1 | 1-OXA-3-AZASPIRO[4,5]DECAN-2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS | Glaxo Group Limited (GB) | 2009-11-18 | — | — | EP | disclosed |
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| WO-2009095377-A1 | SPIRO COMPOUNDS AS NPY Y5 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-08-06 | — | — | WO | disclosed |
| US-20090042897-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| WO-2008129007-A1 | BENZIMIDAZOLES WITH A HETERO SPIRO-DECANE RESIDUE AS NPY-Y5 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008092888-A1 | 1-OXA-3-AZASPIRO[4,5]DECAN--2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008092891-A1 | 1-OXA-3-AZASPIRO(4.5)DECAN-2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008092887-A1 | I-OXA-3-AZASPIRO (4.5) DECAN-2-ONE AND 1-OXA-3, 8-DIAZASPIRO (4.5) DECAN-2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008092887-A1 | I-OXA-3-AZASPIRO (4.5) DECAN-2-ONE AND 1-OXA-3, 8-DIAZASPIRO (4.5) DECAN-2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | NPY4R, NPY1R, NPY5R | OPRM1 139/4885SIGMAR1 74/4885NPY5R 3/4885 |
| US-20100197699-A1 | I-OXA-3-Azaspiro (4.5) Decan-2-One And 1-OXA-3, 8-Diazaspiro (4.5) Decan-2-One Derivatives For The Treatment of Eating Disorders | NPY5R, NPY1R, NPY4R | OPRM1 63/4885SIGMAR1 52/4885NPY5R 1/4885 |
| US-20090042897-A1 | Chemical Compounds | NPY5R, NPY1R, NPY2R | OPRM1 183/4885SIGMAR1 216/4885NPY5R 1/4885 |
| US-20100216821-A1 | Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 Antagonists | NPY5R, NPY4R, NPY1R | OPRM1 74/4885SIGMAR1 42/4885NPY5R 1/4885 |
| US-20100286151-A1 | 1-OXA-3-Azaspiro[4,5]Decan--2-One Derivatives For The Treatment Of Eating Disorders | NPY5R, NPY1R, NPY4R | OPRM1 73/4885SIGMAR1 92/4885NPY5R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.